MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-17-2026
ClearPoint Neuro General and Administrative Expenses 2011-2026 | CLPT
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses ClearPoint Neuro
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.5 M | 12 M | 11.8 M | 9.61 M | 8 M | 5.27 M | 4.3 M | 4.33 M | 4.05 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.5 M | 4.05 M | 8.42 M |
Quarterly General and Administrative Expenses ClearPoint Neuro
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.59 M | 3.39 M | 4.08 M | - | 3.14 M | 2.76 M | 2.83 M | - | 2.9 M | 3.18 M | 2.96 M | - | 2.4 M | 2.66 M | 2.18 M | - | 2.44 M | 1.98 M | 1.66 M | - | 1.25 M | 1.21 M | 1.28 M | - | 1.03 M | 1.03 M | 933 K | - | 1.08 M | 1.09 M | 953 K | - | 867 K | 936 K | 984 K | - | 1.89 M | 1.89 M | 1.97 M | - | 2.13 M | 2.19 M | 2.29 M | - | 2.06 M | 1.93 M | 1.8 M | - | 1.7 M | 1.7 M | 1.63 M | - | 1.44 M | 1.8 M | 1.34 M | - | 1.37 M | 1.11 M | 1.24 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.08 M | 867 K | 1.92 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AdaptHealth Corp.
AHCO
|
382 M | $ 13.13 | 0.11 % | $ 1.77 B |  USA |
 |
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | USA |
 |
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | USA |
 |
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
43.5 M | $ 10.71 | 3.18 % | $ 384 M | USA |
 |
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | USA |
 |
Second Sight Medical Products
EYES
|
1.11 M | - | -0.97 % | $ 54.4 M | USA |
 |
Electromed
ELMD
|
39.3 M | $ 25.72 | 0.04 % | $ 217 M | USA |
 |
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | USA |
 |
Helius Medical Technologies
HSDT
|
9.27 M | $ 2.09 | 2.41 % | $ 1.27 M | USA |
 |
Aziyo Biologics
AZYO
|
15.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
EDAP TMS S.A.
EDAP
|
5.9 M | $ 3.34 | 0.6 % | $ 125 M |  France |
 |
Inspire Medical Systems
INSP
|
625 M | $ 56.12 | -0.04 % | $ 1.65 B | USA |
 |
BioSig Technologies
BSGM
|
67.5 M | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | USA |
 |
LivaNova PLC
LIVN
|
549 M | $ 60.16 | 0.1 % | $ 3.28 B |  Britain |
 |
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.65 | 5.74 % | $ 40.5 M | USA |
 |
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | USA |
 |
Invacare Corporation
IVC
|
227 M | - | - | $ 24.7 M | USA |
 |
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
IRIDEX Corporation
IRIX
|
7.73 M | $ 1.06 | 2.91 % | $ 18 M | USA |
 |
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | USA |
 |
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M |  Canada |
 |
OrthoPediatrics Corp.
KIDS
|
120 M | $ 15.36 | 1.96 % | $ 360 M | USA |
 |
Sintx Technologies
SINT
|
6.2 M | $ 2.17 | 4.33 % | $ 6.02 M | USA |
 |
Butterfly Network
BFLY
|
39.8 M | $ 4.93 | 2.92 % | $ 1.04 B | USA |
 |
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | USA |
 |
Stryker Corporation
SYK
|
8.65 B | $ 301.88 | -4.2 % | $ 115 B | USA |
 |
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | USA |
 |
TransMedics Group
TMDX
|
185 M | $ 99.82 | -0.96 % | $ 3.39 B | USA |
 |
Tandem Diabetes Care
TNDM
|
445 M | $ 19.88 | 1.82 % | $ 1.35 B | USA |
 |
Globus Medical
GMED
|
1.18 B | $ 90.91 | 0.81 % | $ 12.3 B | USA |
 |
NanoVibronix
NAOV
|
7.63 M | - | - | $ 1.08 M | USA |
 |
CONMED Corporation
CNMD
|
132 M | $ 36.73 | 0.19 % | $ 1.14 B | USA |
 |
Integer Holdings Corporation
ITGR
|
212 M | $ 85.82 | -3.04 % | $ 2.98 B | USA |
 |
Vivos Therapeutics
VVOS
|
27.7 M | $ 0.83 | 3.7 % | $ 8.53 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
2.09 B | $ 83.6 | 0.12 % | $ 48.9 B | USA |
 |
LENSAR
LNSR
|
45.2 M | $ 5.43 | 3.82 % | $ 64.9 M | USA |
 |
Pulmonx Corporation
LUNG
|
101 M | $ 1.4 | 9.38 % | $ 57 M | USA |
 |
MiMedx Group
MDXG
|
56.5 M | $ 3.56 | 5.8 % | $ 526 M | USA |